+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04153422

Study of Intravenous Immunoglobulin Panzyga Treatment for Adults with Autoimmune Small Fiber Neuropathy Caused by TS-HDS, FGFR-3, or Plexin D1 Antibodies

Led by Endeavor Health · Updated on 2026-01-09

20

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of an intravenous immunoglobulin IVIG called Panzyga to treat patients with small fiber neuropathy SFN, a condition that causes pain and nerve damage. This study focuses on patients with autoimmune SFN who have specific antibodies TS-HDS, FGFR-3, or Plexin D1. While Panzyga is approved for other immune-related conditions, it has not yet been approved for SFN. The purpose is to see if Panzyga can improve nerve fiber density and reduce pain in these patients. Participants will be randomly assigned to receive either Panzyga IVIG or a placebo. Those in the treatment group will receive 2gkg of IVIG every four weeks over two days 1gkg on each day for a total of six doses over 24 weeks. The placebo group will get saline infusions on the same schedule. This double-blind trial compares the effects of IVIG against placebo over six months. During the study, participants will undergo skin biopsies before and after treatment to measure nerve fiber density, which is the primary outcome after 24 weeks. Secondary assessments include pain ratings, disability scales, symptom questionnaires, and neurological exams at baseline and week 28. Patients will be monitored regularly to track symptoms and safety throughout the trial, which is expected to complete by February 2028.

CONDITIONS

Brief Title

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Research Team

A

Anna Pham

M

May Aunaetitrakul

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here